🇺🇸 FDA
Patent

US 10906985

Targeted engineered interferon and uses thereof

granted A61KA61K2039/55522A61K38/00

Quick answer

US patent 10906985 (Targeted engineered interferon and uses thereof) held by Orionis Biosciences, Inc expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Orionis Biosciences, Inc
Grant date
Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/55522, A61K38/00, A61K47/60, A61P